Creatine for women: what new trials in perimenopause and menopause actually found

Creatine monohydrate is one of the most extensively studied supplements in sports nutrition, but for most of that research history the study populations skewed heavily toward young men, leaving real uncertainty about whether the same benefits and dosing applied to women, particularly across the hormonal shifts of the menstrual cycle, pregnancy, and menopause. A newer wave of trials specifically enrolling women has started closing that gap, with results that are broadly, though not uniformly, favorable.

A meta-analysis pooling multiple randomized trials in postmenopausal women found creatine supplementation, generally combined with resistance training, produced measurable increases in lean mass and strength gains beyond resistance training alone — relevant given that the drop in estrogen at menopause accelerates muscle loss, making this a population with a specific, mechanistically plausible reason to benefit.

A notable newer finding extends beyond muscle: a randomized trial specifically in peri- and menopausal women found creatine supplementation improved reaction time and increased frontal-lobe creatine levels measurably, alongside signals of benefit for mood symptom severity — a cognitive and mood angle that's relatively new territory for creatine research and specifically relevant to a population navigating the cognitive and mood shifts common around menopause. Safety data in this population, including from a dedicated trial in peri- and menopausal women, has shown no severe adverse effects at standard dosing.

The standard dosing recommendation — 3 to 5 grams of creatine monohydrate daily, taken consistently rather than cycled — applies to women the same way it does to men; the newer research doesn't suggest a different dosing strategy, just a broader and more specifically documented set of reasons for women, particularly around perimenopause and menopause, to consider it alongside resistance training.